Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Silence Therapeutics plcNASDAQ: SLN

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$15.02M, compared with -$36.75M a year earlier. Trailing-twelve-month operating income was -$86.59M.

Context

  • Operating income amounted to 16056.0% of revenue in FY2025, up 15909.6 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 4 analysts of -$3.84M (+95.7%) for the fiscal year ending Dec 2026, a step up from the -41.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$15.02M-20.5% QoQ
Last fiscal yearDec 2025
-$89.75M-41.7% YoY
LTMMar 2026
-$86.59M— YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.1%+95.7%+36.6 pp
1 year-41.7%+95.7%+137.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

Mixed currencies · from the income statement

Latest · FY2025
(89.75M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How SLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Operating income amounts to 9396.6% of revenue for SLN, versus a peer median of 196.7%.
SLN Competitors
Operating Income for SLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026-$40.96M USD+65.1%—1.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€46.45M EUR-39.8%—345.5%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$53.94M USD-43.9%——
RNAAtrium Therapeutics, Inc.FY2025-$76.81M USD——412.6%
SLNSilence Therapeutics plcLTM Mar 2026-$86.59M USD——9396.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$89.22M USD-8.7%—196.7%
WVEWave Life Sciences Ltd.LTM Mar 2026-$196.88M USD-56.6%—274.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$565.42M USD-103.4%—58.9%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$707.17M USD-819.1%—156.9%
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding SLN) —-43.9%—196.7%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Revenue12.42M17.65M25.38M43.26M559K
Cost of Revenue7.46M10.97M10.32M11.81M215K
Gross Profit4.96M6.68M15.06M31.45M344K
Gross Margin39.9%37.8%59.3%72.7%61.5%
Research & Development30.77M35.5M44.03M67.88M67.75M
Selling, General & Admin20.01M20.94M20.64M26.88M22.34M
Operating Expenses50.77M56.44M64.66M94.77M90.1M
Depreciation & Amortization427K485.86K498K593K555K
EBITDA(45.42M)(39.94M)(49.78M)(48.99M)(88.05M)
EBITDA Margin-365.9%-226.2%-196.2%-113.2%-15750.6%
Operating Income(45.81M)(49.76M)(49.6M)(63.32M)(89.75M)
Operating Margin-369.0%-281.9%-195.5%-146.4%-16056.0%
Interest Income10K226K1.45M4.47M3.48M
Interest Expense8K47K34K00
Other Income / Expenses(42K)9.29M(706K)18.86M1.15M
Income Before Tax(45.86M)(40.47M)(50.31M)(44.46M)(88.6M)
Pre-Tax Margin-369.4%-229.3%-198.3%-102.8%-15849.9%
Income Tax Expense(6.45M)560.85K(7.04M)845K11K
Net Income(39.41M)(41.03M)(43.27M)(45.31M)(88.61M)
Net Margin-317.4%-232.4%-170.5%-104.7%-15851.9%
EPS (Basic)(1.35)(3.78)(3.48)(2.37)(1.89)
EPS (Diluted)(1.35)(3.78)(3.48)(2.37)(1.89)
Weighted Avg Shares29.65M10.73M12.36M15.42M47.23M
Weighted Avg Shares (Diluted)29.65M10.73M12.36M15.42M47.23M

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.